Who is Online

We have 132 guests and no members online

 

 

In Part1, in July 2023, Wendy and I travelled north from Los Angeles to Seattle, Washington, and then Vancouver, in Canada, from where we made our way east to Montreal.

In Part2, in August 2023, we flew from Montreal, Quebec, Canada, down to Miami, Florida, then Ubered to Fort Lauderdale, where we joined a western Caribbean cruise.

Florida W Caribbean10

At the end of the cruise, we flew all the way back up to Boston.

From Boston we hired another car to drive, down the coast, to New York.

After New York we flew to Salt Lake City, Nevada, then on to Los Angeles, California, before returning to Sydney.

No comments

Travel

Hong Kong and Shenzhen China

 

 

 

 

 

Following our Japan trip in May 2017 we all returned to Hong Kong, after which Craig and Sonia headed home and Wendy and I headed to Shenzhen in China. 

I have mentioned both these locations as a result of previous travels.  They form what is effectively a single conurbation divided by the Hong Kong/Mainland border and this line also divides the population economically and in terms of population density.

These days there is a great deal of two way traffic between the two.  It's very easy if one has the appropriate passes; and just a little less so for foreign tourists like us.  Australians don't need a visa to Hong Kong but do need one to go into China unless flying through and stopping at certain locations for less than 72 hours.  Getting a visa requires a visit to the Chinese consulate at home or sitting around in a reception room on the Hong Kong side of the border, for about an hour in a ticket-queue, waiting for a (less expensive) temporary visa to be issued.

With documents in hand it's no more difficult than walking from one metro platform to the next, a five minute walk, interrupted in this case by queues at the immigration desks.  Both metros are world class and very similar, with the metro on the Chinese side a little more modern. It's also considerably less expensive. From here you can also take a very fast train to Guangzhou (see our recent visit there on this website) and from there to other major cities in China. 

Read more: Hong Kong and Shenzhen China

Fiction, Recollections & News

A Womens' view

 

Introduction

 

The following article presents a report by Jordan Baker, as part of her history assignment when she was in year 10 at North Sydney Girls’ High School.   For this assignment she interviewed her mother, grandmother and great-grandmother about their lives as girls; and the changes they had experienced; particularly in respect of the freedoms they were allowed.

Read more: A Womens' view

Opinions and Philosophy

The race for a SARS-CoV-2 vaccine

 

 

 

 

As we all now know (unless we've been living under a rock) the only way of defeating a pandemic is to achieve 'herd immunity' for the community at large; while strictly quarantining the most vulnerable.

Herd immunity can be achieved by most people in a community catching a virus and suffering the consequences or by vaccination.

It's over two centuries since Edward Jenner used cowpox to 'vaccinate' (from 'vacca' - Latin for cow) against smallpox. Since then medical science has been developing ways to pre-warn our immune systems of potentially harmful viruses using 'vaccines'.

In the last fifty years herd immunity has successfully been achieved against many viruses using vaccination and the race is on to achieve the same against SARS-CoV-2 (Covid-19).

Developing; manufacturing; and distributing a vaccine is at the leading edge of our scientific capabilities and knowledge and is a highly skilled; technologically advanced; and expensive undertaking. Yet the rewards are potentially great, when the economic and societal consequences of the current pandemic are dire and governments around the world are desperate for a solution. 

So elite researchers on every continent have joined the race with 51 vaccines now in clinical trials on humans and at least 75 in preclinical trials on animals.

Read more: The race for a SARS-CoV-2 vaccine

Terms of Use

Terms of Use                                                                    Copyright